ZG006 and ZG005 in Participants With Small Cell Lung Cancer or Neuroendocrine Carcinoma

A Phase Ib/II Study of the Tolerability, Safety, Efficacy, and Pharmacokinetics of ZG006 in Combination With ZG005 in Participants With Advanced Small Cell Lung Cancer or Neuroendocrine Carcinoma(NEC)

This study is a randomized, multicenter, Phase Ib/II clinical trial, aimed at evaluating the efficacy and safety of the combination of ZG006 and ZG005 in patients with advanced small cell lung cancer and neuroendocrine carcinoma.

Inclusion Criteria:

• Fully understand the study and voluntarily sign the informed consent form.
• Male or female 18-70 years of age.
• Participants with advanced small cell lung cancer or neuroendocrine carcinoma confirmed by histopathology or cytology.
• Eastern Cooperative Oncology Group (ECOG) 0 to 1.
• Life expectancy > 3 months.

Exclusion Criteria:

• The investigator believes that the subject has other reasons that make them unsuitable for participation in this study.